Exhibit 99.1
 | Proposed issue of securities |
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
22/11/2023
The Proposed issue is:
An offer of securities under a securities purchase plan
Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan
| ASX +security code | | +Security description | | Maximum Number of
+securities to be issued | |
| New class-code to be confirmed | | Short-dated option | | | 571,428,571 | |
| New class-code to be confirmed | | Long-dated option | | | 190,476,191 | |
| ATH | | ORDINARY FULLY PAID | | | 571,428,571 | |
+Record date
21/11/2023
Offer closing date
31/1/2024
+Issue date
7/2/2024
Refer to next page for full details of the announcement
| Proposed issue of securities | 1 / 10 |
| Proposed issue of securities |
| Part 1 - Entity and announcement details | |
| | |
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
| 1.2 | Registered Number Type | Registration Number |
ATH
New announcement
| 1.5 | Date of this announcement |
22/11/2023
| 1.6 | The Proposed issue is: |
An offer of +securities under a +securities purchase plan
| Proposed issue of securities | 2 / 10 |
| Proposed issue of securities |
| Part 4 - Details of proposed offer under securities purchase plan | |
| | |
4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?
Yes
4A.1a Conditions
| Approval/Condition | | Date for determination | | Is the date estimated or actual? | | ** Approval
received/condition met? |
| +Security holder approval | | 29/12/2023 | | Estimated | | | |
Comments
| Proposed issue of securities | 3 / 10 |
| Proposed issue of securities |
Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued
ASX +security code and description
ATH : ORDINARY FULLY PAID
Will the proposed issue of this +security include an offer of attaching +securities?
Yes
Details of +securities proposed to be issued
ASX +security code and description
ATH : ORDINARY FULLY PAID
Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted
571,428,571
Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?
No
Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?
No
Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?
No
Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?
Yes
Is the maximum acceptance unit based or dollar based?
Dollar based ($)
Please enter the maximum acceptance value
$ 30,000
Describe all the applicable parcels available for this offer in number of securities or dollar value
| Parcels are yet to be determined and will be advised in the offer document. |
| Proposed issue of securities | 4 / 10 |
| Proposed issue of securities |
Offer price details
Has the offer price been determined?
Yes
| In what currency will the offer be made? | What is the offer price per +security? |
| AUD - Australian Dollar | AUD 0.00350 |
Oversubscription & Scale back details
Will a scale back be applied if the offer is over-subscribed?
Yes
Describe the scale back arrangements
| The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. |
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
Attaching +Security
The proposed attaching security can only be of an ‘Existing class’ (additional +securities in a class that is already quoted or recorded by ASX)
New class
Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)
Details of attaching +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from ASX that the terms
of the proposed +securities are appropriate and
equitable under listing rule 6.1? | | Will the entity be seeking quotation of the ‘new’ class of
+securities on ASX? |
| No | | No |
| | | |
| ASX +security code | | +Security description |
| New class-code to be confirmed | | Short-dated option |
+Security type
Options
| Proposed issue of securities | 5 / 10 |
| Proposed issue of securities |
Offer ratio (ratio of attaching securities at which the new +securities will be issued)
| The quantity of attaching +securities to be issued | For a given quantity of the new +securities issued |
| 1 | 1 |
| | |
| What will be done with fractional entitlements? | Maximum total number of those +securities that could be
issued if all offers under the +securities purchase plan
are accepted |
Fractions rounded down to the nearest whole number or
fractions disregarded | 571,428,571 |
Offer price details
Has the offer price been determined?
No
How and when will the offer price be determined?
| Free attaching short-dated option per Placement announcement 22 November 2023. |
Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan
No
Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS
Yes
Over subscription & Scale back details
Will a scale back be applied if the offer is over-subscribed?
Yes
Describe the scale back arrangements
| The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. |
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Options details
| +Security currency | |
| AUD - Australian Dollar | |
| | |
Exercise price AUD 0.0070 | Expiry date 31/8/2024 |
Details of the type of +security that will be issued if the option is exercised
ATH : ORDINARY FULLY PAID
| Proposed issue of securities | 6 / 10 |
| Proposed issue of securities |
Number of securities that will be issued if the option is exercised
| One ATH ordinary fully paid share |
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.
| https://alteritytherapeutics.com/investor-overview/asx-announcements/ |
Details of attaching +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from ASX that the terms
of the proposed +securities are appropriate and
equitable under listing rule 6.1? | | Will the entity be seeking quotation of the ‘new’ class of
+securities on ASX? |
| No | | Yes |
| | | |
| ASX +security code | | +Security description |
| New class-code to be confirmed | | Long-dated option |
+Security type
Options
Offer ratio (ratio of attaching securities at which the new +securities will be issued)
| The quantity of attaching +securities to be issued | For a given quantity of the new +securities issued |
| 1 | 3 |
| What will be done with fractional entitlements? | Maximum total number of those +securities that could be
issued if all offers under the +securities purchase plan
are accepted |
Fractions rounded down to the nearest whole number or
fractions disregarded | 190,476,191 |
Offer price details
Has the offer price been determined?
No
How and when will the offer price be determined?
| One (1) free attaching long-dated option per three (3) shares issued under SPP per Placement announcement 22 November 2023. |
Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan
No
Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS
Yes
| Proposed issue of securities | 7 / 10 |
| Proposed issue of securities |
Oversubscription & Scale back details
Will a scale back be applied if the offer is over-subscribed?
Yes
Describe the scale back arrangements
| The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. |
Will all the +securities issued in this class rank equally in all respects from their issue date
Yes
Options details
+Security currency
AUD - Australian Dollar
| Exercise price | Expiry date |
| AUD 0.0100 | 31/8/2026 |
Details of the type of +security that will be issued if the option is exercised
ATH : ORDINARY FULLY PAID
Number of securities that will be issued if the option is exercised
| One ATH ordinary fully paid share |
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.
| https://alteritytherapeutics.com/investor-overview/asx-announcements/ |
| Proposed issue of securities | 8 / 10 |
| Proposed issue of securities |
4C.1 Date of announcement of +security purchase plan
22/11/2023
4C.2 +Record date
21/11/2023
4C.3 Date on which offer documents will be made available to investors
12/1/2024
4C.4 Offer open date
12/1/2024
4C.5 Offer closing date
31/1/2024
4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer
7/2/2024
| Part 4D - Listing Rule requirements | |
| | |
4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?
No
4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
No
4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity’s additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
| Proposed issue of securities | 9 / 10 |
| Proposed issue of securities |
| Part 4E - Fees and expenses | |
| | |
4E.1 Will there be a lead manager or broker to the proposed offer?
No
4E.2 Is the proposed offer to be underwritten?
No
4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?
No
4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer
| Part 4F - Further Information | |
| | |
4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
| The use of proceeds from this financing will provide ongoing funding of Alterity’s Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital. |
4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
No
4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer
| All countries except Australia and New Zealand |
4F.3 URL on the entity’s website where investors can download information about the proposed offer
| https://alteritytherapeutics.com/investor-overview/asx-announcements/ |
4F.4 Any other information the entity wishes to provide about the proposed offer
| Proposed issue of securities | 10 / 10 |
